Invasive fungal infection by *Aspergillus flavus* in immunocompetent hosts: A case series and literature review

Ana María Garcia-Giraldo⁴, Barbara Lucia Mora⁵, Jorge Mario Loaiza-Castaño⁶, Jorge Andrés Cedano⁵, Fernando Rosso⁵,⁶,⁎

⁴ Facultad de Ciencias de la Salud, Universidad ICESI, Calle 18 # 122-135, Cali, Colombia
⁵ Clinical Research Center, Fundación Valle del Lili, Carrera 98 #18–49, Cali, Colombia
⁶ Facultad de Medicina, Universidad CES, Calle 10A #22–04, Medellín, Colombia

⁎ Corresponding author at: Clinical Research Center, Fundación Valle del Lili, Carrera 98 #18–49, Cali, Colombia.

E-mail addresses: ayahuasca21@yahoo.com (A.M. Garcia-Giraldo), barbara.mora@fvl.org.co (B.L. Mora), jmario2050@hotmail.com (J.M. Loaiza-Castaño), jorge.cedano@fvl.org.co (J.A. Cedano), fernando.rosso@fvl.org.co, frosso07@gmail.com (F. Rosso).

The management of these patients should be multidisciplinary to establish an adequate antifungal treatment with surgical debridement to prevent recurrence and search for factors that are predisposing the infection of this microorganism.

1. Introduction

Paranasal sinus aspergillosis (PNSA) can be invasive or non-invasive. The latter is more common, has a better prognosis and can be presented as an allergic sinusitis. This type of infection destroys the mucosa but does not invade the bone tissues [1,2]. On the other hand, invasive aspergillosis more commonly affects the lung, followed by sinuses and gastrointestinal tract. Additionally, it has a worse prognosis with high morbidity and mortality due to an intracranial and intraorbital extension, with a mortality rate that ranges between 35% and 90%, primarily in the immunocompromised hosts [1,3].

The invasive form of the infection occurs most frequently in immunocompromised patients such as those with HIV, diabetes mellitus (DM), cirrhosis, cancer, use of immunosuppressive agents or transplantation [4]. There are few reports of invasive aspergillosis affecting immunocompetent patients, features shared by both cases presented below.

As for the diagnosis of this entity, and due to the wide variety of differential diagnosis, multiple studies are required, such as diagnostic images, biopsy for pathological study and microbiological isolation of the fungus. Nevertheless, isolation may take a considerable amount of time and delay the diagnosis [4].

2. Case

2.1. Case #1

A 42-year-old female patient with past medical history of obesity and a bariatric surgery consults for a year of symptoms consisting in progressive bilateral exophthalmos, especially on the left side, associated with eye pain, bilateral hyaline rhinorrhea and headache, without a change in visual capacity. Upon consultation to the emergency room (day 0), a brain MRI was performed, with a nasopharynx-dependent mass invasion of the anterior cerebral fossa, orbit and maxillary and frontal sinuses finding (see Fig. 1-B). At first, it was diagnosed as an invasive nasopharyngeal tumor associated with cerebrospinal fluid (CSF) fistula, which was scheduled for surgical resection.

She was admitted for tumor resection through bifrontal craniotomy with transnasal endoscopic approach (day +69). On admission, the...
The patient was stable, without motor or sensory deficits at the neurological physical exam. After tumor resection, the microbiological study of the lesion was performed, where KOH showed septate hyaline hyphae on day +71 and the culture was positive for *Aspergillus flavus* (day +75) (see Fig. 1-A). Pathological analysis reported invasion of all the nasal respiratory mucosa by a granulomatous inflammatory infiltrate, with a few foci of necrosis and extensive areas of fibrosis, giant cells and histiocytes that had septated hyaline hyphae phagocytized. The bone fragments were surrounded by the same type of inflammatory infiltrate. The coloring of PAS and Gomori allowed identification of the typical hyphae of *Aspergillus* in the respiratory mucosa and bone tissue. The patient received amphotericin B 50 mg IV q 24 h from day 70 to day 75, and subsequently, after the identification of *A. flavus*, management was changed to voriconazole 200 mg PO q12hours during 6 months.

On day +74, multiple extension studies were performed, including a negative serum galactomannan (0.326), a negative HIV serology, normal immunoglobulin G 14.4 g/l, CD4: 660 cells/µl (normal), CD3:1042 cells/µl (normal), and a computed tomography scan (CT scan) of the thorax, where a right apical pulmonary nodule with frosted glass pattern was reported, suggestive of initial infection by *Aspergillus*. Afterward, bronchoscopy and bronchoalveolar lavage (BAL) were performed (day +76), with galactomannan in BAL reported positive (result: 0.718, positive: > 0.5).

Laboratory tests, including complete blood count (CBC), kidney and liver function tests (LFT) were within normal limits during the hospitalization. Protein electrophoresis showed moderate decline in albumin.

During the post-operative, the patient persisted with a cerebrospinal fluid fistula and received acetazolamide from day +78 to day +98. The remaining clinical course was uneventful, and patient was discharged on day +89 with full recovery and without recurrence.

### 2.2. Case #2

A 76-year-old female patient with a history of hypothyroidism managed with levothyroxine 50 g/day and recurrent left eye chronic dacryocystitis by Methicillin-resistant S. aureus (MRSA) (day −27). Required reconstructive surgery of the left lacrimal pathway (day 0), where a lacrimal duct lesion extending to the adenoid region was found, and resection of the lacrimal duct bone was also performed. The pathology report showed lymphoplasmacytic severe chronic inflammatory infiltrate in soft tissue and fragments of bone with osteomyelitis, as well as a mass that revealed septate hyphae and some irregular, partially pigmented with occasional formation of conidial heads of *Aspergillus* in the microbiological examination (day +13). In the fungal culture, *Aspergillus flavus* was isolated (day +26); thus craniofacial invasive aspergillosis was diagnosed, and management with voriconazole 200 mg PO q12h was initiated on day +13 and continued for three months (day +103). Extension studies were performed on day +14, which reported a normal CBC, kidney function, and LFT, negative serum galactomannan (0.315), negative HIV, a brain MRI showing microangiopathic leukoencephalopathy without others abnormalities and a thorax CT scan that reported nonspecific thickening of interlobular septae. The patient’s clinical course was adequate without recurrence of the disease.

### 3. Discussion

Invasive PNSA can be presented as a local or fulminant form and it is more commonly associated with immunocompromised hosts [2]. Significant risk factors include neutrophil defects, steroid treatment, chemotherapy, AIDS, chronic granulomatous disease and bone marrow or solid organ transplantation [1,2,4], which were not present in any of the two cases we presented. The most frequently found Aspergillus subspecies on invasive infections is the *A. fumigatus* species complex [4]. In a study that included 218 cases of infections on transplantation centers in North America [5], 67% of infections were due to members of the *A. fumigatus* species complex, followed by *A. flavus* (13%), *A. niger* (9%), and *A. terreus* (7%). Nevertheless, it is more common to find *A. flavus* in paranasal sinuses and skin infections [4]. Even if the patients we presented were not immunosuppressed, it is possible that specific factors were involved in acquiring the infection. For instance, in the first case, the patient had a history of bariatric surgery, so it is possible that specific nutritional deficits, such as vitamin B12, iron, and folic acid deficit could disrupt the immune system. In the second case, the patient had a previous dacryocystitis infection by *Staphylococcus aureus*, which according to the previously published literature, could increase the risk of infection by *Aspergillus* due to a mechanical obstruction of the lacrimal ducts [6].

#### 3.1. Differential diagnosis of fungal infections in the immunocompetent host

It is a medical challenge to differentiate between neoplastic disease and invasive fungal infection since they are clinically similar and the imaging findings are not conclusive, hereby biopsies with pathological study are useful in these situations. In the first case, the initial diagnostic impression was a neoplasm, and then pathologic and microbiologic study revealed invasive aspergillosis. Proving that imaging, pathology, and microbiology studies are essential to guide an adequate treatment [7].

Other authors suggest the measurement of galactomannan and β-(1,3)-d-glucan (BDG), which are components of the fungal cell wall, can be useful in the diagnosis. Galactomannan can be measured in serum or in a bronchoalveolar lavage, and it is relatively specific for *Aspergillus*, with a 71% sensitivity and an 89% specificity [8]. The 2016 IDSA guidelines [2] recommend using it in immunosuppressed patients, excluding its use in chronic granulomatous diseases and solid organ recipients. On the other hand, BDG can be detected in other fungal infections and has a 64% sensitivity and 84% specificity [8]. The IDSA guidelines recommend using BDG for invasive aspergillosis in high-risk patients, such as those with hematologic malignancies and allogeneic stem cell transplantation. More recently, the IDSA recommends employment of molecular methods when isolates report atypical growth or concerns for resistance are present [2].

#### 3.2. Delayed diagnosis and treatment of invasive fungal infection in the immunocompetent host

A late diagnosis of this condition is related to therapeutic failure and progression of the disease, ultimately leading to complications and death of the patient [9]. In both of the cases reported in this article, there was a delay in the diagnosis. Fortunately, both patients evolved adequately. This delay has also been reported in previous reports, such LaBarbera et al. and Baeesa et al., where appropriate treatment was not
Table 1

| Author | Age | Gender | Comorbidities | Site of infection | Aspergillus species | Management | Outcome |
|--------|-----|--------|---------------|------------------|-------------------|------------|---------|
| Carpio CJ et al. | 69 | Male | None | Lung | A. terreus | Voriconazole | Recovery |
| Bunkar ML et al. | 19 | Male | None | Lung and thorax | A. fumigatus | Recovery |
| | 15 | Female | None | Lung | A. flavus and fumigatus | Recovery |
| | 15 | Male | None | Oral cavity | A. flavus and fumigatus | Recovery |
| | 19 | Male | None | Lung | A. fumigatus | Amphotericin B and surgery | Demise |
| Moreno-González G et al. | 56 | Female | Immobilization | Disseminated (lungs, heart, brain, and kidneys) | Not specified | Voriconazole, caspofungin and amphotericin | Demise |
| Dimitrakopoulos I et al. | 64 | Male | None | Paranasal sinuses, orbit and cranial fossa | Not specified | Amphotericin B and surgical intervention | Demise |
| Hersh CM et al. | 55 | Female | Alcohol Use | The optic nerve, cavernous sinus, and other airway sites | Not specified | Voriconazole | Recovery |
| Kim JH et al. | 29 | Male | None | Lung | A. fumigatus | Voriconazole | Recovery |
| Ratermann KL et al. | 51 | Female | Near Drowning experience | Lung | A. fumigatus | Amphotericin B and Voriconazole | Demise |
| Subramanian S et al. | 40 | Male | None | Orbit, brain and pterygopalatine fossa | Not specified | Amphotericin and surgery | No follow up |
| Kwon OK et al. | 60 | Male | Influenza A, HTN | Lung | Not specified | Voriconazole | Recovery |
| Bajaj N et al. | 22 | Male | None | Heart | A. fumigatus | Voriconazole | Recovery |
| Mohammed AP et al. | 33 | Female | None | Lungs | A. fumigatus | Caspofungin and Voriconazole | Recovery |
| Baeesa SS et al. | 14–53 | 4 - Female | Not specified | Orbital apex with an intracranial aneurysm and SAH | Not specified | Amphotericin B and Surgery | 5/6 deceased |

SAH: Subarachnoid hemorrhage.

Six patients were included in this study.

3.3. Other cases reported in the literature and their outcomes

Cases of invasive aspergillosis on immunocompetent hosts have been published previously. Table 1 summarizes 14 published articles so far with the report of 19 cases. The ages of the patients described ranged from 14 to 70 years of age, with 10 female and 9 male patients. The majority of the papers report the isolation of A. fumigatus species complex (6 out of 7 cases that reported a species) with a demise outcome in 9 of the total 19 cases included in this literature review. The most common site of infection is the lung and thorax (8/19), followed by head and neck (11/19), especially, paranasal sinuses with further dissemination to the orbit and brain. This finding is consistent with the fact that Aspergillus infects via inhalation of its spores. Therefore lungs, sinuses, and other airway sites may be the most commonly affected sites [13].

In conclusion, the invasive PNSA is an aggressive and uncommon condition in immunocompetent patients, has a high rate of morbidity and mortality even with adequate medical/surgical treatment [9] and requires performing of imaging and pathologic study to obtain a definitive diagnosis given the wide range of differential diagnosis. Moreover, it is essential to perform further studies that elicit the type of immune response immunocompetent patients develop against Aspergillus infection, to understand the mechanisms leading to the disease.

Acknowledgments

Fundación Valle del Lili, Cali, Colombia.

Conflict of interest

There are none.

References

[1] A.P. Mohammed, P. Dhunputh, R. Chiluka, S. Umakanth, An unusual case of invasive aspergillosis in an immunocompetent individual, BMJ Case Rep. 2015 (2015), https://doi.org/10.1136/bcr-2015-210381 (bcr2015210381).
[2] T.F. Patterson, G.R. Thompson, D.W. Denning, J.A. Fishman, S. Hadley, R. Herbrecht, D.P. Kontoyiannis, K.A. Marr, V.A. Morrison, M.H. Nguyen, B.H. Segal, W.J. Steinbach, D.A. Stevens, T.J. Walsh, J.R. Wingard, J.A.H. Young, J.E. Bennett, Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America, Clin. Infect. Dis. 63 (2016) e1–e60.
[3] A. Akhaddar, M. Gazzaz, B. Limouni, B. Elmostarchid, M. Boucetta, Invasive Aspergillus terreus sinusitis with orbital extension: case report, Surg. Neurol. 69 (2008) 490–495, https://doi.org/10.1016/j.surneu.2007.02.059.
[4] T.F. Patterson, Aspergillus species, in: Mand Douglass, Princ Bennett's (Eds.), Pract. Infect. Dis., Eighth Edi, Elsevier Inc, 2014, pp. 2895–2908.
[5] K.A. Marr, R.A. Carter, F. Crippa, A. Wald, L. Corey, Epidemiology and outcome of mold infections in hematopoietic stem cell transplant recipients, Clin. Infect. Dis. 34 (2002) 909–917, https://doi.org/10.1086/339202.
[6] H. Wang, A. Ramakrishnan, S. Fletcher, E.V. Prochownik, M. Genetics, Acute Chiasmal abscess resulting from perineural extension of invasive sino-orbital aspergillosis in an Immunocompetent individual, BMJ Case Rep. 2015 (2015), https://doi.org/10.1136/bcr-2015-213205 (bcr2015213205).
[7] N. Bajaj, D. Chadha, P. Hasija, H.S. Arora, Invasive aspergillosis presenting as an intracardiac mass in an immunocompetent host, BMJ Case Rep. (2016), https://doi.org/10.1136/bcr-2015-213205 (bcr2015213205).
[8] M. Kousha, R. Tadi, A.O. Soubani, Pulmonary aspergillosis: a clinical review, Eur. Respir. Rev. 20 (2011) 156–174, https://doi.org/10.1183/09059180.00001011.
[9] I. Dimitrakopoulos, N. Lazaridis, A. Asimaki, Cranial-facial invasive aspergillosis in an immunocompetent patient: a case report, J. Oral Maxillofac. Surg. 63 (2005) 845–848, https://doi.org/10.1016/j.joms.2005.02.022.
[10] M. LaBarbera, L.B. Jacobson, Invasive aspergillosis in an immunocompetent patient with fever and a cardiac mass, Infect. Dis. Rep. 3 (2011), https://doi.org/10.4081/idr.2011.e12.

[11] S.S. Baeesa, M. Bakhaidar, N.A.B. Ahamed, T.A. Madani, Invasive orbital apex aspergillosis with mycotic aneurysm formation and subarachnoid hemorrhage in immunocompetent patients, World Neurosurg. 102 (2017) 42–48, https://doi.org/10.1016/j.wneu.2017.02.096.

[12] H. Mouss, I. Lutsar, B. Dupont, O. Pain, R. Herbrecht, F.-X. Lesure, O. Lortholary, Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases, Clin. Infect. Dis. 40 (2005) 1141–1147, https://doi.org/10.1086/428734.

[13] M. Rasolinejad, M. Hajabdolbaghi, S.A. Dehghani, F. Azmoudeh Arslan, P. Moradnejad, N. Alijani, Cerebral aspergillosis in an immunocompetent patient: a case report, Arch. Neurosci. 3 (2015), https://doi.org/10.5812/archneurosci.3170.

[14] C.J. Carpio Segura, A. Santiago Recuerda, C. Prados Sánchez, A. Gómez Mendieta, I. Fernández Navarro, R. Alvárez-Sala, Aspergilosis pulmonar invasiva debido a Aspergillus terreus en un paciente immunocompetente con enfermedad pulmonar obstructiva crónica, Rev. Patol. Respir. 14 (2011) 23–25, https://doi.org/10.1016/S1576-9895(11)70099-6.

[15] M. Lal Bunkar, R.P. Takhar, S. Arya, Invasive pulmonary aspergillosis presenting as thoracic mass causing obstruction of the superior and inferior vena cava in an immunocompetent patient: a diagnostic dilemma, Ann. Saudi Med. 35 (2015) 409–413, https://doi.org/10.5144/0256-4947.2015.409.

[16] G. Moreno-González, A. Ricart De Mesones, R. Tazi-Mezalek, M.T. Marron-Moya, A. Rosell, R. Maínez, Invasive pulmonary aspergillosis with disseminated infection in immunocompetent patient, Can. Respir. J. 2016 (2016) 1–6, https://doi.org/10.1155/2016/7984032.

[17] B. Abir, A. Abouchadi, J. Hamama, M. Ouakabi, M. Nassih, A. Rzn, Aspergillose invasive du sinus maxillaire chez un patient immunocomptént, Rev. Stomatol. Chir. Maxillofac. 113 (2012) 127–130, https://doi.org/10.1016/j.rscm.2011.12.011.

[18] C.M. Hersh, S. John, A. Subei, M.A. Willis, G.S. Kosmorsky, R.A. Prayson, A. Bhimraj, Optic neuropathy and stroke secondary to invasive aspergillus in an immunocompetent patient, J. Neuro-Ophthalmol. 36 (2016) 404–407, https://doi.org/10.1016/j.jono.2016.02.011.

[19] J.H. Kim, H.L. Lee, L. Kim, J.S. Kim, Y.J. Kim, H.Y. Lee, K.H. Lee, Airway centered invasive pulmonary aspergillosis in an immunocompetent patient: case report and literature review, J. Thorac. Dis. 8 (2016) E250–E254, https://doi.org/10.21037/jtd.2016.02.23.

[20] K.L. Ratermann, B.J. Ereshefsky, E.L. Fleishaker, A.C. Thornton, K.P. Buch, C.A. Martin, Fulminant invasive pulmonary aspergillosis after a near-drowning accident in an immunocompetent patient, Ann. Pharmacother. 48 (2014) 1225–1229, https://doi.org/10.1177/1060028014537961.

[21] S. Subramanian, H. Kandpal, R. Sharma, N. Pushkar, S. Sen, S. Gamanagatti, S. Vashist, Invasive sinus aspergillosis with perineural spread in an immunocompetent patient, Australas. Radiol. 51 (2007) B189–B192, https://doi.org/10.1111/j.1440-1673.2007.01838.x.

[22] O.K. Kwon, M.G. Lee, H.S. Kim, M.S. Park, K.M. Kwak, S.Y. Park, Invasive pulmonary aspergillosis after influenza a infection in an immunocompetent patient, Tuberc. Respir. Dis. 75 (2013) 260–263, https://doi.org/10.4046/trd.2013.75.6.260.